[Articles] PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

The favourable outcome of patients treated with eBEACOPP could not be improved by adding rituximab after positive PET-2. PET-2 negativity allows reduction to only four cycles of eBEACOPP without loss of tumour control. PET-2-guided eBEACOPP provides outstanding efficacy for all patients and increases overall survival by reducing treatment-related risks for patients with negative PET-2. We recommend this PET-2-guided treatment strategy for patients with advanced-stage Hodgkin's lymphoma.

Source: LANCET - October 20, 2017 Category: General Medicine Authors: Peter Borchmann, Helen Goergen, Carsten Kobe, Andreas Lohri, Richard Greil, Dennis A Eichenauer, Jos ée M Zijlstra, Jana Markova, Julia Meissner, Michaela Feuring-Buske, Andreas Hüttmann, Judith Dierlamm, Martin Soekler, Hans-Joachim Beck, Wolfgang Will Tags: Articles Source Type: research